NO331689B1 - Oral farmasoytisk sammensetning omfattende rivastigmin, samt anvendelse av rivastigmin - Google Patents
Oral farmasoytisk sammensetning omfattende rivastigmin, samt anvendelse av rivastigmin Download PDFInfo
- Publication number
- NO331689B1 NO331689B1 NO20011471A NO20011471A NO331689B1 NO 331689 B1 NO331689 B1 NO 331689B1 NO 20011471 A NO20011471 A NO 20011471A NO 20011471 A NO20011471 A NO 20011471A NO 331689 B1 NO331689 B1 NO 331689B1
- Authority
- NO
- Norway
- Prior art keywords
- rivastigmine
- composition
- pharmaceutical composition
- cellulose
- water
- Prior art date
Links
- 239000008203 oral pharmaceutical composition Substances 0.000 title claims description 7
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims abstract description 53
- 229960004136 rivastigmine Drugs 0.000 claims abstract description 50
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims description 62
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 33
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 32
- 238000000576 coating method Methods 0.000 claims description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- 239000011248 coating agent Substances 0.000 claims description 27
- 239000008188 pellet Substances 0.000 claims description 21
- 239000000126 substance Substances 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 18
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 16
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 16
- 239000001856 Ethyl cellulose Substances 0.000 claims description 15
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 15
- 229920001249 ethyl cellulose Polymers 0.000 claims description 15
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 14
- 235000010980 cellulose Nutrition 0.000 claims description 13
- 229920002678 cellulose Polymers 0.000 claims description 13
- 239000001913 cellulose Substances 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 13
- 238000013270 controlled release Methods 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 7
- 206010012289 Dementia Diseases 0.000 claims description 4
- 239000007916 tablet composition Substances 0.000 claims description 3
- 239000013543 active substance Substances 0.000 abstract description 19
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 21
- 239000002775 capsule Substances 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 17
- 229910001220 stainless steel Inorganic materials 0.000 description 17
- 239000010935 stainless steel Substances 0.000 description 17
- 238000011049 filling Methods 0.000 description 16
- 239000003826 tablet Substances 0.000 description 15
- 229940079593 drug Drugs 0.000 description 12
- 239000003960 organic solvent Substances 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 239000000377 silicon dioxide Substances 0.000 description 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 9
- 235000019359 magnesium stearate Nutrition 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 description 9
- 239000008108 microcrystalline cellulose Substances 0.000 description 9
- 239000008213 purified water Substances 0.000 description 9
- 235000012239 silicon dioxide Nutrition 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 239000007921 spray Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- -1 hydrogen ions Chemical class 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 238000009792 diffusion process Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 229920000620 organic polymer Polymers 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 239000010839 body fluid Substances 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000000314 lubricant Substances 0.000 description 5
- 229910052710 silicon Inorganic materials 0.000 description 5
- 239000010703 silicon Substances 0.000 description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229940124531 pharmaceutical excipient Drugs 0.000 description 4
- 239000011253 protective coating Substances 0.000 description 4
- 229940081735 acetylcellulose Drugs 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 229920002301 cellulose acetate Polymers 0.000 description 3
- 239000007891 compressed tablet Substances 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 229940108366 exelon Drugs 0.000 description 3
- 239000013563 matrix tablet Substances 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-M L-tartrate(1-) Chemical compound OC(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-M 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 235000011132 calcium sulphate Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical group 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 229950010673 rivastigmine hydrogen tartrate Drugs 0.000 description 2
- GWHQHAUAXRMMOT-MBANBULQSA-N rivastigmine tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 GWHQHAUAXRMMOT-MBANBULQSA-N 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 102100033639 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 108010053652 Butyrylcholinesterase Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102100032404 Cholinesterase Human genes 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical class CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001756 Polyvinyl chloride acetate Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229920002433 Vinyl chloride-vinyl acetate copolymer Polymers 0.000 description 1
- SMEGJBVQLJJKKX-HOTMZDKISA-N [(2R,3S,4S,5R,6R)-5-acetyloxy-3,4,6-trihydroxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)OC(=O)C)O)O SMEGJBVQLJJKKX-HOTMZDKISA-N 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000001175 calcium sulphate Substances 0.000 description 1
- 229940096529 carboxypolymethylene Drugs 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 239000007771 core particle Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000005243 fluidization Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000010514 hydrogenated cottonseed oil Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 229940039371 karaya gum Drugs 0.000 description 1
- 239000003350 kerosene Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 239000012907 medicinal substance Substances 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 239000012184 mineral wax Substances 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229920001281 polyalkylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 102220060547 rs786203080 Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- LDHQCZJRKDOVOX-UHFFFAOYSA-N trans-crotonic acid Natural products CC=CC(O)=O LDHQCZJRKDOVOX-UHFFFAOYSA-N 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229920006163 vinyl copolymer Polymers 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9821298.8A GB9821298D0 (en) | 1998-10-01 | 1998-10-01 | Organic compoundsq |
GBGB9821299.6A GB9821299D0 (en) | 1998-10-01 | 1998-10-01 | Organic compounds |
GBGB9826654.7A GB9826654D0 (en) | 1998-12-03 | 1998-12-03 | Organic compounds |
GBGB9827624.9A GB9827624D0 (en) | 1998-12-16 | 1998-12-16 | Organic compounds |
GBGB9907822.2A GB9907822D0 (en) | 1999-04-06 | 1999-04-06 | Organic compounds |
GBGB9907823.0A GB9907823D0 (en) | 1999-04-06 | 1999-04-06 | Organic compounds |
PCT/EP1999/007298 WO2000019985A2 (fr) | 1998-10-01 | 1999-10-01 | Nouvelles formulations administrees par voie orale et a liberation prolongee |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20011471L NO20011471L (no) | 2001-03-22 |
NO20011471D0 NO20011471D0 (no) | 2001-03-22 |
NO331689B1 true NO331689B1 (no) | 2012-02-27 |
Family
ID=27547321
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20011471A NO331689B1 (no) | 1998-10-01 | 2001-03-22 | Oral farmasoytisk sammensetning omfattende rivastigmin, samt anvendelse av rivastigmin |
Country Status (23)
Country | Link |
---|---|
US (5) | US20010033866A1 (fr) |
EP (1) | EP1121104B1 (fr) |
JP (1) | JP4012689B2 (fr) |
KR (1) | KR100603900B1 (fr) |
CN (1) | CN1406126A (fr) |
AT (1) | ATE286725T1 (fr) |
AU (1) | AU764866B2 (fr) |
BR (1) | BR9914251A (fr) |
CA (1) | CA2342340C (fr) |
CZ (1) | CZ302888B6 (fr) |
DE (1) | DE69923200T2 (fr) |
ES (1) | ES2237163T3 (fr) |
HK (1) | HK1052473A1 (fr) |
HU (1) | HUP0103883A3 (fr) |
ID (1) | ID27504A (fr) |
IL (2) | IL141762A0 (fr) |
NO (1) | NO331689B1 (fr) |
NZ (1) | NZ510683A (fr) |
PL (1) | PL196945B1 (fr) |
PT (1) | PT1121104E (fr) |
SK (1) | SK285250B6 (fr) |
TR (1) | TR200100931T2 (fr) |
WO (1) | WO2000019985A2 (fr) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL141762A0 (en) * | 1998-10-01 | 2002-03-10 | Novartis Ag | New oral formulations |
WO2000030446A1 (fr) * | 1998-11-23 | 2000-06-02 | Bonnie Davis | Formulations de dosage d'inhibiteurs de l'acetylcholinesterase |
WO2001013898A2 (fr) * | 1999-08-26 | 2001-03-01 | Elan Corporation, Plc. | Compositions pharmaceutiques |
GB9923045D0 (en) * | 1999-09-29 | 1999-12-01 | Novartis Ag | New oral formulations |
NZ524641A (en) * | 2000-09-29 | 2004-09-24 | Solvay Pharmaceuticals B | A pharmaceutical hydrophilic gel forming matrix formulation having prolonged release which is ion strength independent |
JP5023412B2 (ja) * | 2001-05-09 | 2012-09-12 | 吉澤石灰工業株式会社 | ホルムアルデヒド廃液の処理剤 |
JP2005525299A (ja) * | 2001-09-14 | 2005-08-25 | スコラー インコーポレイテッド | アミノ酸調節性の長期放出投薬形態 |
DE60223695T2 (de) * | 2001-09-14 | 2008-10-30 | Scolr, Inc., Redmond | Aminosäure-modulierte dosierform mit verlängerter freisetzung |
KR100453288B1 (ko) * | 2002-03-12 | 2004-10-21 | 한국화학연구원 | 약물의 제어 방출을 위한 스퀴즈-유형의 삼투성 약물 전달장치 |
PT1529116E (pt) * | 2002-08-07 | 2009-09-10 | Novartis Ag | Métodos para o tratamento da demência com base no genótipo da apo e |
AU2003100262B4 (en) * | 2003-04-07 | 2003-09-18 | Jurox Pty Ltd | Stable carprofen composition |
US20060105036A1 (en) * | 2003-05-12 | 2006-05-18 | Stephen Peroutka | Threo-dops controlled release formulation |
US8158149B2 (en) * | 2004-05-12 | 2012-04-17 | Chelsea Therapeutics, Inc. | Threo-DOPS controlled release formulation |
ATE454138T1 (de) * | 2003-08-08 | 2010-01-15 | Biovail Lab Int Srl | Tablette mit modifizierter freisetzung von bupropion hydrochlorid |
WO2006020534A2 (fr) * | 2004-08-09 | 2006-02-23 | Dr. Reddy's Laboratories Ltd. | Composition stabilisee |
WO2006123357A2 (fr) * | 2005-02-22 | 2006-11-23 | Sun Pharmaceutical Industries Limited | Composition pharmaceutique |
JP2008540437A (ja) * | 2005-05-03 | 2008-11-20 | ミユーチユアル・フアーマシユーチカルズ・カンパニー・インコーポレーテツド | キニーネを含有する制御放出調合剤 |
JP5209966B2 (ja) * | 2005-09-01 | 2013-06-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 崩壊性の改善された医薬組成物の製造方法 |
GB0525461D0 (en) | 2005-12-15 | 2006-01-25 | Archimedes Dev Ltd | Pharmaceutical compositions |
GB0606562D0 (en) * | 2006-03-31 | 2006-05-10 | Novartis Ag | Organic compounds |
EP2019679B1 (fr) | 2006-05-23 | 2018-06-20 | Theracos, Inc. | Inhibiteurs de transport de glucose et procédés d'utilisation |
US8748419B2 (en) | 2006-06-16 | 2014-06-10 | Theracos, Inc. | Treating obesity with muscarinic receptor M1 antagonists |
US7893053B2 (en) | 2006-06-16 | 2011-02-22 | Theracos, Inc. | Treating psychological conditions using muscarinic receptor M1 antagonists |
AR065913A1 (es) | 2007-04-02 | 2009-07-08 | Theracos Inc | Derivados de glicosido bencilico, composicion y combinacion farmaceutica y uso |
ITMI20071502A1 (it) * | 2007-07-25 | 2009-01-26 | Archimica Srl | Procedimento per la preparazione di formulazioni solide a rilascio controllato contenenti oxcarbazepina e formulazioni ottenibili con tale procedimento |
WO2009022345A1 (fr) * | 2007-08-14 | 2009-02-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Carbamates de phényle destinés au traitement de la sclérose en plaques |
LT2187742T (lt) | 2007-08-23 | 2018-01-10 | Theracos Sub, Llc | (2s,3r,4r,5s,6r)-2-(4-chlor-3-benzilfenil)-6-(hidroksimetil)tetrahidro-2h-piran-3,4,5-triolio dariniai, skirti panaudoti diabeto gydymui |
EP2197454A4 (fr) * | 2007-09-25 | 2012-07-04 | Idexx Lab Inc | Compositions pharmaceutiques pour l'administration d'oligonucléotides |
US20110201597A1 (en) * | 2008-03-27 | 2011-08-18 | Chase Thomas N | Method and composition for treating alzheimer-type dementia |
FR2931677B1 (fr) * | 2008-06-02 | 2010-08-20 | Sanofi Aventis | Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs |
BRPI0916769A2 (pt) | 2008-07-15 | 2017-09-26 | Theracos Inc | derivados de benzilbenzeno deuterados e métodos de uso |
NZ604897A (en) | 2008-08-22 | 2014-03-28 | Theracos Sub Llc | Processes for the preparation of sglt2 inhibitors |
JP5930278B2 (ja) | 2008-11-25 | 2016-06-08 | ユニバーシティー オブ ロチェスター | Mlk阻害剤および使用方法 |
MX345236B (es) | 2009-09-18 | 2017-01-23 | Chase Pharmaceuticals Corp | Metodo y composicion para tratar la demencia de tipo alzheimer. |
US20110150986A1 (en) * | 2009-12-18 | 2011-06-23 | Kristin Arnold | Quinine formulations, method of making, and metho of use thereof |
CN101797236B (zh) * | 2010-03-23 | 2012-05-23 | 西南大学 | 重酒石酸卡巴拉汀口腔崩解片及其制备方法 |
CN103153994B (zh) | 2010-05-24 | 2016-02-10 | 罗切斯特大学 | 双环杂芳基激酶抑制剂及使用方法 |
WO2011151359A1 (fr) | 2010-06-02 | 2011-12-08 | Noscira, S.A. | Traitement combiné comprenant un inhibiteur de la cholinestérase et un dérivé de thiadiazolidinedione |
WO2011153712A1 (fr) | 2010-06-12 | 2011-12-15 | Theracos, Inc. | Forme cristalline d'inhibiteur de sglt2 de type benzyl-benzène |
ES2716865T3 (es) | 2011-02-18 | 2019-06-17 | Scripps Research Inst | Diferenciación dirigida de células precursoras de oligodendrocitos a un destino celular mielinizante |
WO2012144463A1 (fr) | 2011-04-18 | 2012-10-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Agent thérapeutique pour les tumeurs |
CA2835330A1 (fr) * | 2011-05-06 | 2012-11-15 | Glaxosmithkline Llc | Formulations de paracetamol a liberation prolongee |
MX353623B (es) * | 2011-05-13 | 2018-01-22 | Eb Ip Hybritabs B V | Sistema de suministro de farmaco. |
US8524664B2 (en) | 2011-06-02 | 2013-09-03 | Colorado Seminary, Which owns and Operates The Univeristy of Denver | Methods of treating overproduction of cortisol using ACTH antagonist peptides |
US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
KR102035877B1 (ko) | 2011-11-14 | 2019-10-23 | 알파시그마 에스.피.에이. | 우울증이 있는 대상체를 위한 치료 양생법 선택을 위한 검정법 및 치료 방법 |
CN104768540A (zh) | 2012-09-05 | 2015-07-08 | 才思制药公司 | 抗胆碱能神经保护组合物和方法 |
CN104884059B (zh) | 2012-11-30 | 2018-08-10 | 罗切斯特大学 | 用于hiv/aids治疗的混合谱系激酶抑制剂 |
BR112015009004A8 (pt) | 2012-12-21 | 2021-07-20 | Eisai R&D Man Co Ltd | forma amorfa de derivado de quinolina e método de produção da mesma |
MX368099B (es) | 2013-05-14 | 2019-09-19 | Eisai R&D Man Co Ltd | Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib. |
AU2014307803A1 (en) | 2013-08-16 | 2016-03-10 | Universiteit Maastricht | Treatment of cognitive impairment with PDE4 inhibitor |
WO2015136446A1 (fr) | 2014-03-11 | 2015-09-17 | Nestec S.A. | Méthodes de choix de traitement par antidépresseur pour traiter la dépression |
CN103877063A (zh) * | 2014-03-24 | 2014-06-25 | 张绪伟 | 一种重酒石酸卡巴拉汀胶囊及其制备方法 |
HRP20221047T1 (hr) | 2014-08-28 | 2022-11-11 | Eisai R&D Management Co., Ltd. | Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju |
CN107427505A (zh) | 2015-02-25 | 2017-12-01 | 卫材R&D管理有限公司 | 用于抑制喹啉衍生物的苦味的方法 |
WO2016140717A1 (fr) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Association d'un antagoniste de pd-1 et d'un inhibiteur des tyrosines kinases vegfr/fgfr/ret pour traiter le cancer |
KR101990951B1 (ko) * | 2015-04-27 | 2019-06-20 | 주식회사 네비팜 | 리바스티그민 함유 서방출 의약조성물 |
US11369623B2 (en) | 2015-06-16 | 2022-06-28 | Prism Pharma Co., Ltd. | Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor |
IL243707A0 (en) | 2016-01-20 | 2016-05-01 | Galmed Res And Dev Ltd | Treatment to regulate the microbiota in the intestine |
WO2019039836A2 (fr) * | 2017-08-22 | 2019-02-28 | 아주대학교산학협력단 | Composition de formulation complexe pour le traitement d'une maladie neurodégénérative |
KR20190036370A (ko) | 2017-09-27 | 2019-04-04 | 서원대학교산학협력단 | 약물의 서방성 제형을 위한 약물전달체 |
CN112739334A (zh) | 2018-07-30 | 2021-04-30 | 拜欧西亚制药公司 | 结晶丙二酸肾上腺素盐 |
CN112546037A (zh) * | 2020-12-08 | 2021-03-26 | 苏州大学 | 卡巴拉汀在制备抗辐射药中的应用 |
CN113398273B (zh) * | 2021-05-14 | 2022-07-19 | 广西壮族自治区中国科学院广西植物研究所 | 木聚糖衍生物作为亲水性缓释材料在制备药物缓释片中的应用 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4014335A (en) * | 1975-04-21 | 1977-03-29 | Alza Corporation | Ocular drug delivery device |
USRE34990E (en) * | 1986-08-07 | 1995-07-04 | Ciba-Geigy Corporation | Oral therapeutic system having systemic action |
DE3805744C2 (de) * | 1987-03-04 | 1999-09-23 | Novartis Ag | Phenylcarbamate zur Hemmung der Acetylcholinesterase |
NL195004C (nl) | 1987-03-04 | 2003-11-04 | Novartis Ag | Fenylcarbamaat bevattend farmaceutisch preparaat. |
US5472710A (en) * | 1988-04-16 | 1995-12-05 | Schwarz Pharma Ag | Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture |
DE3922167A1 (de) * | 1988-04-16 | 1991-01-17 | Sanol Arznei Schwarz Gmbh | Oral zu verabreichende diltiazemhydrochlorid enthaltende pharmazeutische zubereitung zur einmal taeglichen applikation und verfahren zu deren herstellung |
US5262173A (en) * | 1992-03-02 | 1993-11-16 | American Cyanamid Company | Pulsatile once-a-day delivery systems for minocycline |
US5260068A (en) * | 1992-05-04 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Multiparticulate pulsatile drug delivery system |
PT621032E (pt) * | 1993-04-23 | 2001-01-31 | Novartis Ag | Dispositivo de distribuicao de libertacao controlada de farmaco |
US5698224A (en) * | 1994-06-27 | 1997-12-16 | Alza Corporation | Tacrine therapy |
US5962535A (en) * | 1997-01-17 | 1999-10-05 | Takeda Chemical Industries, Ltd. | Composition for alzheimer's disease |
GB9701695D0 (en) | 1997-01-28 | 1997-03-19 | De Beers Ind Diamond | Insert for an abrasive tool |
DE19707655A1 (de) * | 1997-02-26 | 1998-08-27 | Hoechst Ag | Kombinationspräparat zur Anwendung bei Demenz |
CN1158071C (zh) * | 1997-05-30 | 2004-07-21 | 渗透有限公司 | 多层渗透装置 |
GB9800526D0 (en) * | 1998-01-12 | 1998-03-11 | Ciba Geigy Ag | Organic compounds |
IL141762A0 (en) | 1998-10-01 | 2002-03-10 | Novartis Ag | New oral formulations |
US6534541B1 (en) | 1999-10-19 | 2003-03-18 | Novartis Ag | Treatment of ocular disorders |
-
1999
- 1999-10-01 IL IL14176299A patent/IL141762A0/xx unknown
- 1999-10-01 AU AU63321/99A patent/AU764866B2/en not_active Ceased
- 1999-10-01 BR BR9914251-1A patent/BR9914251A/pt not_active Application Discontinuation
- 1999-10-01 WO PCT/EP1999/007298 patent/WO2000019985A2/fr not_active Application Discontinuation
- 1999-10-01 PT PT99950595T patent/PT1121104E/pt unknown
- 1999-10-01 HU HU0103883A patent/HUP0103883A3/hu unknown
- 1999-10-01 ID IDW20010671A patent/ID27504A/id unknown
- 1999-10-01 CA CA002342340A patent/CA2342340C/fr not_active Expired - Fee Related
- 1999-10-01 TR TR2001/00931T patent/TR200100931T2/xx unknown
- 1999-10-01 PL PL348734A patent/PL196945B1/pl not_active IP Right Cessation
- 1999-10-01 DE DE69923200T patent/DE69923200T2/de not_active Expired - Lifetime
- 1999-10-01 EP EP99950595A patent/EP1121104B1/fr not_active Expired - Lifetime
- 1999-10-01 NZ NZ510683A patent/NZ510683A/en not_active IP Right Cessation
- 1999-10-01 CN CN99811633A patent/CN1406126A/zh active Pending
- 1999-10-01 KR KR1020017003384A patent/KR100603900B1/ko not_active IP Right Cessation
- 1999-10-01 ES ES99950595T patent/ES2237163T3/es not_active Expired - Lifetime
- 1999-10-01 AT AT99950595T patent/ATE286725T1/de active
- 1999-10-01 JP JP2000573347A patent/JP4012689B2/ja not_active Expired - Fee Related
- 1999-10-01 CZ CZ20011155A patent/CZ302888B6/cs not_active IP Right Cessation
- 1999-10-01 SK SK439-2001A patent/SK285250B6/sk not_active IP Right Cessation
-
2001
- 2001-03-01 IL IL141762A patent/IL141762A/en unknown
- 2001-03-22 NO NO20011471A patent/NO331689B1/no not_active IP Right Cessation
- 2001-03-27 US US09/818,690 patent/US20010033866A1/en not_active Abandoned
-
2002
- 2002-04-08 US US10/118,183 patent/US6565883B2/en not_active Expired - Fee Related
-
2003
- 2003-03-31 US US10/403,146 patent/US20030203025A1/en not_active Abandoned
- 2003-07-09 HK HK03104925.9A patent/HK1052473A1/zh unknown
-
2005
- 2005-04-14 US US11/105,967 patent/US20050175706A1/en not_active Abandoned
-
2006
- 2006-11-03 US US11/592,853 patent/US20070053982A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO331689B1 (no) | Oral farmasoytisk sammensetning omfattende rivastigmin, samt anvendelse av rivastigmin | |
RU2235540C2 (ru) | Способ получения пероральной препаративной формы пролонгированного действия с регулируемым высвобождением активного вещества в зависимости от вида и количества наполнения желудка и пищеварительного тракта | |
JPH10511407A (ja) | 高用量難溶性薬物用持続放出マトリックス | |
CN102105136A (zh) | 包含非-阿片类止痛剂和阿片类止痛剂的组合的胃滞留型缓释剂型 | |
NO311918B1 (no) | Filmbelagt tablett av astemizol og pseudoefedrin, med forlenget frigivelse, samt fremgangsmåte ved fremstilling av denne | |
JP5420590B2 (ja) | pH非依存延長放出性医薬組成物 | |
JPH01250314A (ja) | 徐放性製剤 | |
JP2005512997A (ja) | タムスロシン錠 | |
EP2726064B1 (fr) | Forme orale pharmaceutique à libération contrôlée contenant oxycodone | |
US20030099710A1 (en) | Granule modulating hydrogel system | |
NO331480B1 (no) | Farmasoytiske sammensetninger med kontrollert frigivelse | |
EP1784161B1 (fr) | Formulation à libération contrôlée comprenant de l'hydrochlorure de tamsulosine | |
JP5919173B2 (ja) | 徐放性塩酸アンブロキソール口腔内崩壊錠 | |
RU2286766C2 (ru) | Новые композиции пролонгированного действия для перорального введения | |
US20040228918A1 (en) | Granule modulating hydrogel system | |
Laicher et al. | Influence of Tablet Formulation and Size on the in Vztro Sustained-Release Behavior of Metoprolol Tartrate from Hydrophilic Matrices | |
MXPA01002365A (en) | New sustained release oral formulations | |
MXPA94008792A (en) | Sustained release formulations for 24 hours of metopro release |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |